H1 revenue growth was an impressive 31% and is all organic. This is testament to the actions taken by management in recent years to broaden the offering and to focus on emerging growth areas such as early phase clinical and electronic regulatory submissions. The outlook remains very positive and we see potentially material upside over the next few years on the back of the FDA’s new SEND initiative in particular.
